Liraglutide

Mechanism

An FDA-approved daily injection that mimics a gut hormone called GLP-1. It slows stomach emptying, reduces appetite, and helps regulate blood sugar. Sold as Victoza for diabetes and Saxenda for weight loss. It's the predecessor to semaglutide.

Effects

GLYCEMIC [Tier 1 – FDA-Approved]: Liraglutide is a once-daily GLP-1 receptor agonist with 97% homology to native human GLP-1, modified with a C16 fatty acid chain for albumin binding (half-life ~13 hours). FDA-approved as Victoza (type 2 diabetes, up to 1.8 mg daily) and Saxenda (weight management, 3.0 mg daily). Reduces HbA1c by 1.0-1.5% in diabetes trials. Second GLP-1 agonist approved after exenatide. WEIGHT LOSS [Tier 1 – FDA-Approved]: SCALE trial program established liraglutide 3.0 mg as an effective weight loss agent. Mean weight loss 5.4-8.0% of body weight over 56 weeks vs 2.6% for placebo. About 63% of patients achieve ≥5% weight loss. Less effective than semaglutide 2.4 mg (which achieves ~15% weight loss) but was the first GLP-1 RA approved specifically for obesity. CARDIOVASCULAR [Tier 1 – Human Clinical / FDA Label]: LEADER trial (n=9340): Liraglutide 1.8 mg reduced MACE by 13% (HR 0.87, CI 0.78-0.97) and cardiovascular death by 22% (HR 0.78) in type 2 diabetes patients with high CV risk. First GLP-1 RA to demonstrate cardiovascular mortality reduction. Landmark trial that changed the treatment algorithm for T2D. PEDIATRIC [Tier 1 – FDA-Approved]: Saxenda approved for adolescents aged 12-17 with obesity (BMI ≥30 kg/m2 or ≥95th percentile with ≥60 kg body weight). One of very few weight management medications approved in pediatric populations. NAFLD/NASH [Tier 2 – Limited Human]: LEAN trial showed liraglutide resolved NASH (non-alcoholic steatohepatitis) in 39% of patients vs 9% placebo. Liver fat reduction is a consistent benefit across GLP-1 agonists, with liraglutide having the earliest clinical evidence.

Practitioner Guide

CLINICAL POSITIONING: Liraglutide is the "second generation" GLP-1 agonist — after exenatide but before semaglutide. In 2026, it competes primarily on: (1) daily dosing flexibility (some patients prefer daily routine over weekly injection anxiety), (2) Saxenda for obesity is well-established with years of post-marketing data, (3) pediatric approval, (4) more gradual onset of action (less intense GI effects for sensitive patients). WHO IS THE IDEAL LIRAGLUTIDE PATIENT: • Patients who prefer daily injection routine (psychological preference — "I take my injection with my morning routine"). • Adolescents with obesity (Saxenda — pediatric approval gives it a unique niche). • Patients who tried semaglutide and found the once-weekly GI effects too intense. Liraglutide daily dosing allows finer dose titration and may be better tolerated. • NASH/fatty liver patients — strongest early evidence in this indication. • Cost-sensitive patients if generic liraglutide becomes available. DOSING: • Victoza (diabetes): Start 0.6 mg SC daily x 1 week → 1.2 mg daily x 1 week → 1.8 mg daily (maintenance). Inject any time of day, with or without meals. Consistent timing preferred. • Saxenda (weight management): Start 0.6 mg SC daily x 1 week → 1.2 mg x 1 week → 1.8 mg x 1 week → 2.4 mg x 1 week → 3.0 mg daily (maintenance). The 5-week titration is critical for tolerability. • If patient cannot tolerate 3.0 mg, 2.4 mg is an acceptable maintenance dose (still produces clinically meaningful weight loss). TITRATION STRATEGY — LIRAGLUTIDE ADVANTAGE: • The daily dosing actually provides a titration advantage over weekly agents. If a patient gets nausea at 1.8 mg, they can stay at 1.2 mg for 2-3 weeks before re-attempting escalation. With weekly agents, each dose change commits the patient to 7 days of that dose level. • "Micro-titration": Some practitioners use 0.3 mg increments (possible with the pen dial). Example: 0.6 → 0.9 → 1.2 → 1.5 → 1.8 → 2.1 → 2.4 → 2.7 → 3.0. Takes longer but maximizes tolerability for GI-sensitive patients. • Anti-nausea support: Same as other GLP-1 agents — small meals, avoid fatty foods, ginger, ondansetron PRN. TRANSITIONING: • Liraglutide → Semaglutide: Most common upgrade path when more weight loss needed. Stop liraglutide, wait 2-3 days (short half-life), start semaglutide 0.25 mg. Some practitioners start semaglutide 0.5 mg since patient has GLP-1 conditioning, but this is aggressive — 0.25 mg start is safer. • Semaglutide → Liraglutide: Downgrade for tolerability. Stop semaglutide, wait 2 weeks (long half-life), start liraglutide 0.6 mg and titrate up. Patient may tolerate liraglutide 3.0 mg even if they could not tolerate semaglutide 1.0 mg — different pharmacokinetic profile. COMPOUNDING vs BRAND: • Liraglutide has NOT been on the FDA shortage list in the same way as semaglutide, so 503B compounding availability is limited. • Brand Saxenda cash price ~$1300-1500/month. Brand Victoza ~$900-1100/month. • Insurance coverage for Saxenda (obesity indication) is inconsistent. Many plans do not cover weight loss medications. Victoza for T2D is generally covered. • Savings programs: Novo Nordisk patient assistance programs can reduce cost significantly. MUSCLE PRESERVATION: • Same protocol as all GLP-1 agents: Protein 1.0-1.5 g/kg goal weight, resistance training 2-3x/week. • SCALE trials showed approximately 39% of weight lost was lean mass (similar to dietary weight loss generally). This underscores the importance of active muscle preservation strategies. • Monitor with body composition assessment (DEXA, bioimpedance) if available. "GLP-1 FACE" CONSIDERATIONS: • Less common with liraglutide than semaglutide simply because weight loss is more gradual and less dramatic. • Still occurs with significant weight loss. Prevention same: adequate protein, slow weight loss rate, collagen support. STOPPING LIRAGLUTIDE — WHAT TO EXPECT: • Appetite returns within 3-5 days (short half-life — faster return than semaglutide). • Weight regain begins within 2-4 weeks if caloric intake rises. • SCALE maintenance data showed patients who continued liraglutide maintained weight loss; those who stopped regained 50-70% of lost weight within 12 months. • Taper option: 3.0 → 2.4 → 1.8 → 1.2 → 0.6 → stop, over 5 weeks. No evidence this prevents rebound, but eases psychological transition.

Dosing Protocols

Contraindications & Cautions

• hard stop — History of pancreatitis
  GLP-1 receptor agonists are associated with increased risk of pancreatitis. Patients with a history of pancreatitis are at substantially elevated risk of recurrence. Cases of acute pancreatitis, including fatal hemorrhagic or necrotizing pancreatitis, have been reported with liraglutide (Victoza/Saxenda prescribing information).
  Action: Do not use. This is a contraindication per prescribing information. Refer to physician for alternative therapies.
• hard stop — Medullary thyroid carcinoma or MEN2 syndrome
  Liraglutide causes dose-dependent thyroid C-cell tumors in rodents. BLACK BOX WARNING: Contraindicated in patients with personal or family history of MTC or MEN2.
  Action: Absolutely contraindicated. Do not use under any circumstances. This is a black box warning per Victoza/Saxenda labeling.
• hard stop — Pregnancy
  Liraglutide has demonstrated embryo-fetal toxicity in animal studies. Weight loss during pregnancy offers no benefit and may cause fetal harm. Discontinue at least 2 months before planned conception due to long washout.
  Action: Discontinue immediately if pregnancy is detected. Do not initiate during pregnancy.
• hard stop — Breastfeeding
  Insufficient data on excretion in human breast milk. Potential risk to nursing infant. Risk-benefit does not support use.
  Action: Do not use while breastfeeding.
• hard stop — Gastroparesis
  GLP-1 agonists significantly delay gastric emptying. In patients with pre-existing gastroparesis, this can cause severe nausea, vomiting, abdominal pain, and dangerous gastric retention.
  Action: Do not use in patients with diagnosed gastroparesis or severe GI motility disorders.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Liraglutide has specific pediatric indications only under physician supervision.
  Action: Do not provide peptide protocols to individuals under 18. Refer to pediatric endocrinologist.
• hard stop — Other GLP-1 receptor agonists
  Concurrent use of multiple GLP-1 receptor agonists causes dangerous additive effects on gastric emptying, appetite suppression, and insulin secretion. Risk of severe GI events, pancreatitis, and hypoglycemia.
  Action: Never combine multiple GLP-1 agonists. Ensure adequate washout before switching.
• requires physician — Insulin
  Concurrent use with insulin significantly increases risk of hypoglycemia. Liraglutide potentiates insulin secretion and may cause dangerously low blood glucose when combined with exogenous insulin.
  Action: Requires physician supervision. Insulin dose reduction typically required. Frequent blood glucose monitoring mandatory.
• requires physician — Sulfonylureas
  Combined with GLP-1 agonist glucose-dependent insulin secretion, severe hypoglycemia risk increases substantially.
  Action: Physician must evaluate sulfonylurea dose reduction before initiating. Blood glucose monitoring required.
• requires physician — History of eating disorders
  GLP-1 agonists cause significant appetite suppression and weight loss which may trigger eating disorder relapse or exacerbate disordered eating behaviors.
  Action: Requires physician evaluation and mental health screening before initiation.
• caution — Gallbladder disease
  GLP-1 agonists are associated with increased risk of cholelithiasis and cholecystitis, likely due to rapid weight loss and altered gallbladder motility. Liraglutide prescribing information documents this risk.
  Action: Monitor for symptoms of gallbladder disease (RUQ pain, nausea). Ultrasound if symptomatic. Use with caution in patients with gallstone history.

Evidence

• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials

  Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ (2025) — Ann Intern Med — PMID: 39761578

  Retatrutide 12mg/week produced greatest weight loss: 22.1% at 48 weeks. Tirzepatide 15mg/week: 17.8% at 72 weeks. Semaglutide 2.4mg/week: 13.9% at 68 weeks. Liraglutide 3.0mg/day: 5.8% at 26 weeks. AEs predominantly gastrointestinal (nausea, vomiting, diarrhea), mostly mild-moderate. Serious AEs rare (0-10%). Retatrutide is most efficacious agent yet tested for obesity without diabetes.

  strong

• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)

  Marso SP, Daniels GH, Tanaka K, Poulter NR, Mann JF, Nauck MA, Goldman B, Lain S, Pocock S, Buse JB (2016) — New England Journal of Medicine — PMID: 27295427

  Liraglutide 1.8 mg daily reduced the rate of first occurrence of MACE by 13% vs placebo (HR 0.87, 95% CI 0.78-0.97) in T2D patients with high cardiovascular risk. All-cause mortality was significantly reduced (HR 0.85). Cardiovascular death was reduced by 22%. Established cardiovascular safety and benefit for GLP-1 RA class.

  strong

• A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)

  Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP (2015) — New England Journal of Medicine — PMID: 26132939

  Liraglutide 3.0 mg daily produced mean weight loss of -8.0% vs -2.6% with placebo over 56 weeks in adults with BMI >= 30 (or >= 27 with comorbidities). 63.2% of liraglutide patients achieved >= 5% weight loss vs 27.1% with placebo. Nausea and diarrhea were most common adverse events. Supported FDA approval for chronic weight management (Saxenda).

  strong

Stacks featuring this peptide

Research Summary

TIER 1 (Human Clinical Trials / FDA-Approved): • LEAD Program (Phase III, diabetes): LEAD-1 through LEAD-6. Liraglutide 1.8 mg reduced HbA1c 1.0-1.5%, superior to exenatide twice-daily (LEAD-6), with weight loss 2-3 kg. • SCALE Program (Phase III, weight management): SCALE Obesity (Pi-Sunyer et al., 2015, NEJM): Liraglutide 3.0 mg produced 8.0% weight loss at 56 weeks (n=3731). 63% achieved ≥5% weight loss. SCALE Maintenance: Helped maintain prior weight loss. • LEADER (Marso et al., 2016, NEJM): Cardiovascular outcomes trial, n=9340, median follow-up 3.8 years. MACE reduced 13% (HR 0.87). CV death reduced 22% (HR 0.78). First GLP-1 RA to show CV mortality reduction. • LEAN (Armstrong et al., 2016, Lancet): Liraglutide 1.8 mg resolved NASH in 39% vs 9% placebo (n=52). Small study but pioneering. • Pediatric approval: Saxenda approved for adolescents 12-17 (2020) based on SCALE Teens trial. TIER 2 (Limited Human / Strong Preclinical): • Real-world effectiveness studies confirming LEAD and SCALE results in clinical practice. • Comparative effectiveness: Liraglutide 3.0 mg produces ~50-60% of the weight loss of semaglutide 2.4 mg. • NASH/NAFLD: Liver fat reduction consistently observed across multiple studies. Mechanism involves reduced hepatic lipogenesis and improved insulin sensitivity. TIER 3 (Preclinical / Mechanistic): • GLP-1R signaling in hepatocytes — direct and indirect (insulin-mediated) mechanisms of liver fat reduction. • Neuroprotective effects: GLP-1R activation reduces neuroinflammation in animal models. Ongoing clinical trials in Alzheimer disease. • Anti-inflammatory effects beyond glucose lowering (reduced CRP, IL-6 in clinical studies). EVIDENCE GAPS: Head-to-head with semaglutide 2.4 mg for weight loss not formally studied (indirect comparisons only). Optimal dose for NASH (1.8 mg vs 3.0 mg) not established. Long-term outcomes beyond LEADER follow-up period limited. Adolescent long-term safety data limited.